HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239

Comprehensive molecular portraits of human breast tumours

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129

Hypoxia as a Modulator of Inflammation and Immune Response in Cancer

Castillo‐Rodríguez, R. A., Trejo‐Solís, C., Cabrera‐Cano, A., Gómez‐Manzo, S., & Dávila‐Borja, V. M. (2022) · Cancers · doi:10.3390/cancers14092291 · Cited by 70

Immunostimulant Hydrogel-Guided Tumor Microenvironment Reprogramming to Efficiently Potentiate Macrophage-Mediated Cellular Phagocytosis for Systemic Cancer Immunotherapy

Liang, J., Jin, X., Luo, G., Zhang, S., Huang, Q., Lin, Y.-T., Deng, X., Wang, J., Chen, W., & Zhang, X. (2023) · ACS Nano · doi:10.1021/acsnano.3c05093 · Cited by 69

How oxygenation shapes immune responses: emerging roles for physioxia and pathological hypoxia

Mirchandani, A. S., Sánchez-García, M. A., & Walmsley, S. R. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01087-5 · Cited by 77

Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development

Cheu, J. W.-S., Chiu, D. K.-C., Kwan, K. K.-L., Yang, C., Yuen, V. W.-H., Goh, C. C., Chui, N. N.-Q., Shen, W., Law, C.-T., Li, Q., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade5111 · Cited by 65

Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47

Tan, W., Tang, H., Jiang, X., Ye, F., Huang, L., Shi, D., Li, L., Huang, X., Li, L., Xie, X., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14462 · Cited by 65

Engineering macrophages to eat cancer: from “marker of self” CD47 and phagocytosis to differentiation

Alvey, C. M., & Discher, D. E. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri1216-516r · Cited by 65

Mapping the topography of spatial gene expression with interpretable deep learning

Chitra, U., Arnold, B. J., Sarkar, H., Sanno, K., Ma, C., Lopez-Darwin, S. L., & Raphael, B. J. (2025) · Nature Methods · doi:10.1038/s41592-024-02503-3 · Cited by 64

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47

Hu, L., Zhuang, W., Chen, M.-J., Liao, J., Wu, D., Zhang, Y., Pang, L., Huang, Y., Mao, T.-Q., Yang, M., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.03.019 · Cited by 64

Leptin signaling and cancer chemoresistance: Perspectives

Candelaria, P. V., Rampoldi, A., Harbuzariu, A., & Gonzalez-Perez, R. R. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i2.106 · Cited by 61

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment

Jiang, Z., Hsu, J. L., Li, Y., Hortobágyi, G. N., & Hung, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01197 · Cited by 62

Long non-coding RNAs in cancer stem cells

Schwerdtfeger, M., Desiderio, V., Kobold, S., Regad, T., Zappavigna, S., & Caraglia, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101134 · Cited by 58

EGFR‐Induced and c‐Src‐Mediated CD47 Phosphorylation Inhibits TRIM21‐Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion

Du, L., Su, Z., Wang, S., Meng, Y., Xiao, F., Xu, D., Li, X., Qian, X., Lee, S. B., Lee, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202206380 · Cited by 61

Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy

Feliz‐Mosquea, Y. R., Christensen, A. A., Wilson, A. S., Westwood, B. M., Varagić, J., Meléndez, G. C., Schwartz, A. L., Chen, Q., Griner, L. A. M., Guha, R., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4884-x · Cited by 58

Targeting HIF-1α by Natural and Synthetic Compounds: A Promising Approach for Anti-Cancer Therapeutics Development

Ghosh, R., Samanta, P., Sarkar, R., Biswas, S., Saha, P., Hajra, S., & Bhowmik, A. (2022) · Molecules · doi:10.3390/molecules27165192 · Cited by 65

Remotely boosting hyaluronidase activity to normalize the hypoxic immunosuppressive tumor microenvironment for photothermal immunotherapy

Liu, Y., Xu, D., Liu, Y., Zheng, X. W., Zang, J., Ye, W., Zhao, Y., He, R., Ruan, S., Zhang, T., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121516 · Cited by 55

Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion

Shao, X., Hua, S., Feng, T., Ocansey, D. K. W., & Yin, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911789 · Cited by 60

CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes

Kosaka, A., Ishibashi, K., Nagato, T., Kitamura, H., Fujiwara, Y., Yasuda, S., Nagata, M., Harabuchi, S., Hayashi, R., Yajima, Y., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200792 · Cited by 58

Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells

Luo, S., Yang, G., Ye, P., Cao, N., Chi, X., Yang, W., & Yan, X. (2022) · Biomolecules · doi:10.3390/biom12060850 · Cited by 54

CD47 Promotes Human Glioblastoma Invasion Through Activation of the PI3K/Akt Pathway

Liu, X., Wu, X., Wang, Y., Li, Y., Chen, X., Yang, W., & Jiang, L. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15155538502359 · Cited by 53

Hypoxic Signalling in Tumour Stroma

Laitala, A., & Erler, J. T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00189 · Cited by 55

The CD47-SIRPα axis is a promising target for cancer immunotherapies

Hao, Y., Zhou, X., Li, Y., Li, B., & Lei, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110255 · Cited by 54

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis

Hu, J., Xiao, Q., Dong, M., Guo, D., Wu, X., & Wang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.593219 · Cited by 51

Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response

Stirling, E. R., Terabe, M., Wilson, A. S., Kooshki, M., Yamaleyeva, L. M., Alexander‐Miller, M. A., Zhang, W., Miller, L. D., Triozzi, P. L., & Soto‐Pantoja, D. R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004712 · Cited by 52

Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration

Giatromanolaki, A. N., Harris, A. L., Banham, A. H., Contrafouris, C., & Koukourakis, M. I. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0756-3 · Cited by 51

Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?

Martori, C., Sánchez-Moral, L., Paul, T., Pardo, J. C., Pous, A. F., de Porras, V. R., & Sarrias, M. (2022) · Cancers · doi:10.3390/cancers14020440 · Cited by 49

Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients

Yuan, J., He, H., Chen, C., Wu, J., Rao, J., & Yan, H. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0957-0 · Cited by 52

Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells

Alhabbab, R. Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00312 · Cited by 51

Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors

Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64

Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy

Song, C. W., Kim, H., Kim, M.-S., Park, H. J., Paek, S.-H., Terezakis, S. A., & Cho, L. C. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.255 · Cited by 58

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma

Liu, F., Jiang, C. C., Yan, X. G., Tseng, H., Wang, C. Y., Zhang, Y. Y., Yari, H., La, T., Farrelly, M. L., Guo, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17704 · Cited by 50

Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy

Taeb, S., Ashrafizadeh, M., Zarrabi, A., Rezapoor, S., Musa, A. E., Farhood, B., & Najafi, M. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009622666211224154952 · Cited by 49

CD47-targeted bismuth selenide nanoparticles actualize improved photothermal therapy by increasing macrophage phagocytosis of cancer cells

Guo, Z., Liu, Y., Zhou, H., Zheng, K., Wang, D., Jia, M., Xu, P., Ma, K., Cui, C., & Wang, L. (2019) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2019.110546 · Cited by 48

CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes

Roberts, D. D., & Isenberg, J. S. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00175.2021 · Cited by 50

Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives

Jiang, C., Sun, H., Jiang, Z., Tian, W., Cang, S., & Yu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1378647 · Cited by 48

Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment

Schito, L. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00209.2018 · Cited by 49

A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma

Gui, C., Wei, J., Chen, Y., Fu, L., Tang, Y., Cao, J., Chen, W., & Luo, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab173 · Cited by 46

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Xu, Y., He, L., Fu, Q., & Hu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759015 · Cited by 51

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes

Wang, X., Ren, H., Zhao, T., Ma, W., Dong, J., Zhang, S., Xin, W., Yang, S., Jia, L., & Hao, J. (2016) · Oncotarget · doi:10.18632/oncotarget.7263 · Cited by 46

The Roles of Mesenchymal Stromal/Stem Cells in Tumor Microenvironment Associated with Inflammation

Trivanović, D. I., Krstić, J., Djordjević, I. O., Mojsilović, S. B., Santibanez, J. F., Bugarski, D. S., & Jauković, A. (2016) · Mediators of Inflammation · doi:10.1155/2016/7314016 · Cited by 51

Luteolin impairs hypoxia adaptation and progression in human breast and colon cancer cells

Monti, E., Marras, E., Prini, P., & Gariboldi, M. B. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173210 · Cited by 47

Targeting the Tumor Microenvironment: A Close Up of Tumor-Associated Macrophages and Neutrophils

Russo, M., & Nastasi, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871513 · Cited by 45

Targeting intratumoral hypoxia to enhance anti-tumor immunity

Semenza, G. L. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.09.002 · Cited by 47

Immunotargeting of Cancer Stem Cells

Köseer, A. S., Gaetano, S. D., Arndt, C., Bachmann, M. P., & Dubrovska, A. (2023) · Cancers · doi:10.3390/cancers15051608 · Cited by 47

Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications

Wang, L., Jin, Z., Master, R. P., Maharjan, C. K., Carelock, M. E., Reccoppa, T. B. A., Kim, M., Kolb, R. H., & Zhang, W. (2022) · Cancers · doi:10.3390/cancers14133287 · Cited by 46

Redox regulation of cancer stem cells: Biology and therapeutic implications

Du, M., Zhang, J., Wicha, M. S., & Luo, M. (2024) · MedComm – Oncology · doi:10.1002/mog2.70005 · Cited by 45

Anticancer effects of anti-CD47 immunotherapy in vivo

Iribarren, K., Buqué, A., Mondragón, L., Xie, W., Lévesque, S., Pol, J. G., Zitvogel, L., Kepp, O., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1550619 · Cited by 46

Regulation of CD47 expression by interferon-gamma in cancer cells

Ye, Z.-H., Jiang, X., Huang, M., Xu, Y., Chen, Y., Yuan, L., Huang, C.-Y., Yu, W., Chen, X., & Lu, J. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101162 · Cited by 45

Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1

Kanamori, A., Matsubara, D., Saitoh, Y., Fukui, Y., Gotoh, N., Kaneko, S., Seiki, M., Murakami, Y., Inoue, J., & Sakamoto, T. (2020) · Oncogene · doi:10.1038/s41388-020-01423-8 · Cited by 44

Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

Luo, S., Jiang, Y., Zheng, A., Zhao, Y., Wu, X., Li, M., Du, F., Chen, Y., Deng, S., Chen, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1064661 · Cited by 50

Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling

Kaur, S., & Roberts, D. D. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.05.005 · Cited by 43

Bioengineering the Oxygen-Deprived Tumor Microenvironment Within a Three-Dimensional Platform for Studying Tumor-Immune Interactions

Bhattacharya, S., Calar, K., Evans, C. M., Petrasko, M., & de la Puente, P. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.01040 · Cited by 39

Inflammation and Myeloid Cells in Cancer Progression and Metastasis

Deng, J., & Fleming, J. B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.759691 · Cited by 44

CD47‐SIRP α Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer

Catalán, R., Orozco‐Morales, M., Hernández‐Pedro, N., Güijosa, A., Colín-González, A. L., Ávila‐Moreno, F., & Arrieta, O. G. (2020) · Journal of Immunology Research · doi:10.1155/2020/9435030 · Cited by 40

Lighting up the fire in the microenvironment of cold tumors: a major challenge to improve cancer immunotherapy

Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39

CD47 promotes cell growth and motility in epithelial ovarian cancer

Wang, C., Lin, M., Hsu, C., Lin, H., Tsai, H., Long, C., Tsai, E., Hsieh, T., & Wu, C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109105 · Cited by 39

Glucose Transporter 1-Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy

Yu, L.-Y., Shueng, P., Chiu, H., Yen, Y.-W., Kuo, T.-Y., Li, C.-R., Liu, M., Ho, C.-H., Ho, T., Wang, B., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c12123 · Cited by 38

Isolation and characterization of a new naturally immortalized human breast carcinoma cell line, KAIMRC1

Ali, R., Samman, N., Zahrani, H. A., Nehdi, A., Rahman, S., Khan, A. L., Balwi, M. A. A., Alriyees, L. A., Alzaid, M., Alaskar, A. S., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3812-5 · Cited by 38

Hypoxia-inducible factors: roles in cardiovascular disease progression, prevention, and treatment

Semenza, G. L. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac089 · Cited by 43

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer

Lau, A. P. Y., Binstock, S. S. K., & Thu, K. L. (2023) · Cancers · doi:10.3390/cancers15215229 · Cited by 39

CSCs in Breast Cancer—One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs

Sulaiman, A., McGarry, S., Han, X., Liu, S., & Wang, L. (2019) · Cancers · doi:10.3390/cancers11081128 · Cited by 36

The Role of Hypoxia-Inducible Factor Isoforms in Breast Cancer and Perspectives on Their Inhibition in Therapy

Kozal, K., & Krześlak, A. (2022) · Cancers · doi:10.3390/cancers14184518 · Cited by 37

Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq

Vishnubalaji, R., & Alajez, N. M. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.09.002 · Cited by 35

Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics

Nayak, V., Patra, S., Singh, K. R., Ganguly, B., Kumar, D. N., Panda, D., Maurya, G. K., Singh, J., Majhi, S., Sharma, R., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116573 · Cited by 37

Construction of a hypoxia-immune-related prognostic panel based on integrated single-cell and bulk RNA sequencing analyses in gastric cancer

Deng, C., Deng, G., Chu, H., Chen, S., Chen, X., Li, X., He, Y., Sun, C., & Zhang, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140328 · Cited by 34

Nanocarrier based approaches for targeting breast cancer stem cells

Pindiprolu, S. K. S. S., Krishnamurthy, P. T., Chintamaneni, P. K., & Karri, V. V. S. R. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1366337 · Cited by 34

Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors

Miller, T. W., Amason, J., Garcin, E. D., Lamy, L., Dranchak, P. K., MacArthur, R., Braisted, J. C., Rubin, J. S., Burgess, T. L., Farrell, C. L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218897 · Cited by 35

Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis

Zhang, X., Wu, L., Xu, Y., Yu, H. J., Chen, Y., Zhao, H., Lei, J., Zhou, Y. J., Zhang, J., Wang, J., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.03.027 · Cited by 34

The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia

Gallez, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853568 · Cited by 35

A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells

Lee, S., Micalizzi, D. S., Truesdell, S. S., Bukhari, S. I. A., Boukhali, M., Story, J. L., Kato, Y., Choo, M., Dey‐Guha, I., Ji, F., et al. (2020) · Genome biology · doi:10.1186/s13059-020-1936-4 · Cited by 32

Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer

Xu, Y., Li, J., Tong, B., Chen, M., Liu, X., Zhong, W., Zhao, J., & Wang, M. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000823 · Cited by 33

Recent advances in nanoparticles-based photothermal therapy synergizing with immune checkpoint blockade therapy

Dai, X., Li, X., Liu, Y., & Yan, F. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110656 · Cited by 34

Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment

Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32

The Hippo-YAP signaling pathway drives CD24-mediated immune evasion in esophageal squamous cell carcinoma via macrophage phagocytosis

Zhou, X., Yan, Z., Hou, J., Zhang, L., Chen, Z., Gao, C., Ahmad, N. H., Guo, M., Wang, W., Han, T., et al. (2024) · Oncogene · doi:10.1038/s41388-023-02923-z · Cited by 34

Hypoxia-induced ZEB1 promotes cervical cancer immune evasion by strengthening the CD47-SIRPα axis

Chen, X., Guo, C.-H., Wang, Z., Yang, Y., Pan, Y.-H., Liang, J.-Y., Sun, M.-G., Fan, L., Li, L., & Wang, W. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01450-4 · Cited by 32

Hypoxia and immunometabolism in the tumor microenvironment: insights into mechanisms and therapeutic potential.

Wu, C., Xu, T.-H., Zhang, H.-Y., Hu, Y., Jiao, J., Qiu, K., Gu, J., Li, W.-Y., & Sun, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217913 · Cited by 32

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis

La, H. T., Tran, D. B. T., Tran, H. M., & Nguyen, L. T. (2021) · Journal of Immunology Research · doi:10.1155/2021/5575260 · Cited by 33

Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers

Si, Y., Zhang, Y., Guan, J.-S., Ngo, H. G., Totoro, A., Singh, A. P., Chen, K., Xu, Y., Yang, E. S.-H., Zhou, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9080882 · Cited by 32

3D bioprinting technology to mimic the tumor microenvironment: tumor-on-a-chip concept

Samadian, H., Jafari, S., Sepand, M. R., Alaei, L., Malvajerd, S. S., Jaymand, M., Ghobadinezhad, F., Jahanshahi, F., Hamblin, M. R., Derakhshankhah, H., et al. (2021) · Materials Today Advances · doi:10.1016/j.mtadv.2021.100160 · Cited by 33

High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment

Sadozai, H., Acharjee, A., Kayani, H. Z., Gruber, T., Gorczynski, R. M., & Burke, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360629 · Cited by 32

Hypoxic tumor microenvironment: Destroyer of natural killer cell function

Zhang, Y., Guo, F., & Wang, Y. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.02.04 · Cited by 32

USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity

Dai, P., Sun, Y., Huang, Z., Liu, Y.-T., Gao, M., Liu, H.-M., Shi, J., He, C. H., Xiang, B., Yao, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59621-5 · Cited by 37

SOD2 acetylation and deacetylation: Another tale of Jekyll and Hyde in cancer

Hjelmeland, A. B., & Patel, R. P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916214116 · Cited by 30

Tumour growth and immune evasion as targets for a new strategy in advanced cancer

Nicolini, A., Ferrari, P., Rossi, G., & Carpi, A. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0142 · Cited by 32

Targeting CD47 as a Novel Immunotherapy for Breast Cancer

Chen, C., Wang, R., Chen, X., Hou, Y., & Jiang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924740 · Cited by 30

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer

Luo, X., Shen, Y., Huang, W., Bao, Y., Mo, J., Yao, L., & Yuan, L. (2023) · Cancer Control · doi:10.1177/10732748231159706 · Cited by 30

BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors

Kim, H., Lin, Q., & Yun, Z. (2019) · Scientific Reports · doi:10.1038/s41598-019-46210-y · Cited by 29

Role of Hypoxia in the Interferon Response

Arnaiz, E., & Harris, A. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821816 · Cited by 28

TSP1‐CD47‐SIRPα signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium

Liu, Y., Li, M., Wei, C., Tang, L., Sheng, Y., Liu, Y., Li, D., Ding, D., Qiu, J., & Zhu, X. (2020) · American Journal of Reproductive Immunology · doi:10.1111/aji.13236 · Cited by 28

Tumour angiogenesis normalized by myo‐inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response

Hafny‐Rahbi, B. E., Brodaczewska, K. K., Collet, G., Majewska, A., Klimkiewicz, K., Delalande, A., Grillon, C., & Kiéda, C. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16399 · Cited by 27

Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity

Lin, H.-J. L., Liu, Y., Lofland, D., & Lin, J. (2022) · Cancers · doi:10.3390/cancers14020285 · Cited by 28

Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade

Alausa, A. O., Lawal, K. A., Babatunde, O. A., Obiwulu, E. N. O., Oladokun, O. C., Fadahunsi, O. S., Celestine, U. O., Moses, E. U., Akaniro, I. R., & Adegbola, P. I. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106264 · Cited by 29

Immunotherapy for HER-2 positive breast cancer

Yang, T., Kang, L., Li, D., & Song, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1097983 · Cited by 29

Ectopic expression of recipient CD47 inhibits mouse macrophage‐mediated immune rejection against human stem cell transplants

Leung, C. S., Li, J., Xu, F., Wong, A. S. L., & Lui, K. O. (2018) · The FASEB Journal · doi:10.1096/fj.201800449r · Cited by 27

Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: The prime suspect in cancer therapeutic resistance

Aria, H., Rezaei, M., Nazem, S., Daraei, A., Nikfar, G., Mansoori, B., Bahmanyar, M., Tavassoli, A., Vakil, M. K., & Mansoori, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947885 · Cited by 26

Hypoxia-Induced Long Noncoding RNA HIF1A- AS2 Regulates Stability of MHC Class I Protein in Head and Neck Cancer

Liao, T., Chen, Y.-H., Li, Z.-Y., Hsiao, A.-C., Huang, Y.-L., Hao, R.-X., Tai, S., Chu, P., Shih, J.-W., Kung, H., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0622 · Cited by 27

Tumor microenvironment-induced tumor cell plasticity: relationship with hypoxic stress and impact on tumor resistance

Zaarour, R. F., Ribeiro, M., Azzarone, B. G., Kapoor, S., & Chouaı̈b, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1222575 · Cited by 25

LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells

Fan, Z., Zheng, W., Li, H., Wu, W., Liu, X., Sun, Z., Hu, H., Du, L., Jia, Q., & Liu, Q. (2020) · Oncology Reports · doi:10.3892/or.2020.7541 · Cited by 25

An antitumor peptide RS17‐targeted CD47, design, synthesis, and antitumor activity

Wang, X., Wang, Y., Hu, J., & Xu, H. (2021) · Cancer Medicine · doi:10.1002/cam4.3768 · Cited by 25

Hypoxia inducible factor-1α (HIF-1α) in breast cancer: The crosstalk with oncogenic and onco-suppressor factors in regulation of cancer hallmarks

Mirzaei, S., Ranjbar, B., Tackallou, S. H., & Aref, A. R. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154676 · Cited by 28

The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets

Lorestani, P., Dashti, M., Nejati, N., Habibi, M. A., Askari, M., Robat-Jazi, B., Ahmadpour, S., & Tavakolpour, S. (2024) · Discover Oncology · doi:10.1007/s12672-024-01256-x · Cited by 24

ID: 1077 Overexpress of CD47 does not alter stemness of MCF-7 breast cancer cells

Nguyen, O. T.-K., Bui, A. N.-T., Vu, N. B., & Pham, P. V. (2017) · Biomedical Research and Therapy · doi:10.15419/bmrat.v4is.351

Overexpress of CD47 does not alter the stemness of MCF-7 breast cancer cells

Nguyen, O. T.-K., Bui, A. N.-T., Vu, N. B., & Pham, P. V. (2016) · Biomedical Research and Therapy · doi:10.7603/s40730-016-0044-2 · Cited by 2

HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling

Bai, J., Chen, W., Zhang, X., Kang, X.-N., Jin, L., Zhang, H., & Wang, Z. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i1.87 · Cited by 74

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)

Wu, F., Pang, H., Li, F., Hua, M., Song, C., & Tang, J. (2024) · Oncology Letters · doi:10.3892/ol.2024.14389 · Cited by 22

Expression of Concern: Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors

Semenza, G. L. (2026) · Clinical Science · doi:10.1042/cs20150451_eoc